46,831 results match your criteria adjuvant radiotherapy


Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?

Breast Cancer Res Treat 2021 Jun 15. Epub 2021 Jun 15.

Division of Surgical Oncology, Department of Surgery, University of Wisconsin, 600 Highland Ave, Madison, WI, 53792, USA.

Purpose: Controversy remains regarding the optimal margin width for patients with ductal carcinoma in situ (DCIS) who undergo breast conserving surgery (BCS).

Methods: Women with a primary DCIS diagnosis were enrolled in a statewide population-based cohort from 1997 to 2006. Patients were surveyed every two years with follow-up data available through 2016. Read More

View Article and Full-Text PDF

Pseudomyogenic Hemangioendothelioma of the Talocalcaneal Coalition: A Case Report.

J Foot Ankle Surg 2021 Apr 20. Epub 2021 Apr 20.

Department of Orthopedics, the First Hospital of China Medical University, Shenyang, Liaoning Province, China. Electronic address:

Pseudomyogenic hemangioendothelioma is a rare soft tissue tumor most often found in the lower extremities and predominantly occurring in males. The talocalcaneal coalition is an anatomic anomaly that develops between the talus and calcaneus bones, can cause hindfoot pain and subtalar joint stiffness, and has a prevalence of less than 1%. We present what is to our knowledge the first case report of a 17-year-old male with pseudomyogenic hemangioendothelioma occurring within a talocalcaneal coalition. Read More

View Article and Full-Text PDF

Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design.

Trials 2021 Jun 14;22(1):397. Epub 2021 Jun 14.

The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU), London, UK.

Background: For patients with early breast cancer considered at very-low risk of local relapse, risks of radiotherapy may outweigh the benefits. Decisions regarding treatment omission can lead to patient uncertainty (decisional conflict), which may be lessened with patient decision aids (PDA). PRIMETIME (ISRCTN 41579286) is a UK-led biomarker-directed study evaluating omission of adjuvant radiotherapy in breast cancer; an embedded Study Within A Trial (SWAT) investigated whether PDA reduces decisional conflict using a cluster stepped-wedge trial design. Read More

View Article and Full-Text PDF

Management of paediatric intracranial ependymoma.

J Pak Med Assoc 2021 Apr;71(4):1288-1289

Section of Neurosurgery, Department of Surgery, Aga Khan University Hospital, Karachi.

Intracranial ependymoma are relatively common paediatric brain tumours, but their eloquent location and high recurrence rate pose a significant challenge. Gross total resection or maximum safe resection followed by adjuvant radiotherapy are currently the standard recommended treatment, although there is still nearly 50% recurrence risk at 5 years. Chemotherapy has shown some promising results after recent advances in molecular understanding of ependymomas, but needs further evaluation before it could be added to the treatment regime. Read More

View Article and Full-Text PDF

Primary Squamous Cell Carcinoma of the Thyroid: A Case Report and Literature Review About a Rare Entity.

Cureus 2021 May 11;13(5):e14963. Epub 2021 May 11.

Pathology, Steward Health Care, Warren, USA.

Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare and aggressive neoplasm that accounts for less than 1% of all thyroid malignancies. Its incidence is higher in females in their fifth and sixth decades of life. The pathophysiology of PSCCT is still a subject of debate as squamous cells are generally absent in the thyroid gland under normal physiologic conditions. Read More

View Article and Full-Text PDF

Adjuvant high-dose-rate interstitial brachytherapy for malignant peripheral nerve sheath tumor of the foot: a case report.

J Contemp Brachytherapy 2021 Jun 18;13(3):338-346. Epub 2021 May 18.

Department of Radiotherapy, IEO European Institute of Oncology IRCCS, Milan, Italy.

Soft tissue sarcomas of the foot are extremely rare and can therefore be misdiagnosed as benign diseases, and be prematurely removed with an unplanned excision. The standard treatment is a wide local excision with an addition of radiotherapy as an alternative to a radical resection (e.g. Read More

View Article and Full-Text PDF

Radiation cystitis: A late effect of radiotherapy in a patient with cervical rhabdomyosarcoma.

J Cancer Res Ther 2021 Apr-Jun;17(2):580-583

Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.

We report the case of a 22-year old female presenting with an embryonal rhabdomyosarcoma of the cervix that was successfully treated by surgery followed by adjuvant radiation therapy and chemotherapy. She subsequently developed radiation cystitis after 10 years of follow-up. She was successfully treated with cystoscopic fulguration. Read More

View Article and Full-Text PDF

Impact of adjuvant radiotherapy on biological and clinical parameters in right-sided breast cancer.

Cancer Radiother 2021 Jun 10. Epub 2021 Jun 10.

Department of Radiation Oncology, HFR Fribourg - Cantonal Hospital, Chemin des Pensionnats 2-6, 1708 Fribourg, Switzerland.

Purpose: In patients with right-sided breast cancer (BC) the liver might be partially irradiated during adjuvant radiotherapy (RT). Thus, we performed a prospective observational study to evaluate the dose delivered to the liver, and its potential biological impact.

Patients And Methods: We enrolled 34 patients with right-sided BC treated with adjuvant RT. Read More

View Article and Full-Text PDF

Local recurrences in western low rectal cancer patients treated with or without lateral lymph node dissection after neoadjuvant (chemo)radiotherapy: An international multi-centre comparative study.

Eur J Surg Oncol 2021 Jun 6. Epub 2021 Jun 6.

Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia; Faculty of Health and Medical Science, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.

Background: In the West, low rectal cancer patients with abnormal lateral lymph nodes (LLNs) are commonly treated with neoadjuvant (chemo)radiotherapy (nCRT) followed by total mesorectal excision (TME). Additionally, some perform a lateral lymph node dissection (LLND). To date, no comparative data (nCRT vs. Read More

View Article and Full-Text PDF

The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly.

Radiat Oncol 2021 Jun 12;16(1):105. Epub 2021 Jun 12.

Department of Radiation Oncology, University of Freiburg - Medical Center, Robert-Koch-Str. 3, 79106, Freiburg, Germany.

Purpose: To examine treatment patterns, oncological outcomes and toxicity rates in elderly patients receiving radiotherapy for cutaneous squamous cell carcinoma (cSCC) of the head-and-neck region.

Material And Methods: In this retrospective single-center analysis, locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) of elderly patients > 65 years with cSCC of the head-and-neck region undergoing radiotherapy between 2010 and 2019 were calculated. The prognostic value of clinicopathological parameters on radiotherapy outcomes was analyzed using the Cox proportional hazards model. Read More

View Article and Full-Text PDF

The role of radiation therapy in the management of cutaneous malignancies. Part I: Diagnostic modalities and applications.

J Am Acad Dermatol 2021 Jun 8. Epub 2021 Jun 8.

Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer, Houston, Texas, USA.

Radiation therapy offers distinct advantages over other currently available treatments for cutaneous malignancies in certain circumstances. Dermatologists and dermatologic surgeons should be familiar with the radiation therapy techniques available in addition to their value and potential limitations in a variety of clinical scenarios. The first article in this 2-part continuing medical education series highlights the mechanisms, modalities, and applications of the most commonly used radiotherapy treatments as they relate to cutaneous oncology. Read More

View Article and Full-Text PDF

The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.

J Cancer Res Clin Oncol 2021 Jun 11. Epub 2021 Jun 11.

Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, Brest, France.

Introduction: The aim of this study was to evaluate prognostic factors in patients with non-metastatic Merkel cell carcinoma (MCC), with a particular focus on immunological markers such as TILs subtyping (CD3, CD8, CD68, FoxP3, PD-L1 and PD-1) and MCPyV.

Methods: Patients treated for a non-metastatic MCC with oncologic surgical resection followed or not by adjuvant radiotherapy between 01/2007 and 12/2018 were analyzed. Local and regional control (LC, RC), distant metastasis-free survival (DMFS) and overall survival (OS) were evaluated. Read More

View Article and Full-Text PDF

Identifying Patterns of Failure and Risk Factors for Recurrence in Patients of Paratesticular Sarcomas: Protocol of a Systematic Review and Meta-Analysis.

Int J Surg Protoc 2021 May 28;25(1):84-91. Epub 2021 May 28.

Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi, IN.

Introduction: Para testicular sarcomas are rare mesenchymal tumors that affect patients of all ages. Unlike other sites of sarcoma, they tend to be of lower grade and have a higher propensity for lymphatic spread. Management is hampered by the small number of patients who differ in terms of tumor grade and histology. Read More

View Article and Full-Text PDF

Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy.

Cancer Manag Res 2021 31;13:4283-4290. Epub 2021 May 31.

Department of Abdominal Cancer, West China Medical School, Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Purpose: The patients with advanced mismatch repair deficiency (dMMR) cancers can benefit from programmed cell death 1 (PD-1) pathway blockade, regardless of the tumor type. Little is known about the prevalence of dMMR in intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (cHCC-CC). This study aimed to assess the mismatch repair (MMR)-related protein expression in patients with ICC and cHCC-CC. Read More

View Article and Full-Text PDF

Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population.

Int J Gynecol Cancer 2021 Jun 10. Epub 2021 Jun 10.

Department of Gynecology and Obstetrics, Aarhus Universitetshospital, Aarhus, Denmark.

Objective: To compare the performance of the new ESGO-ESTRO-ESP (European Society of Gynecological Oncology-European Society for Radiotherapy & Oncology-European Society for Pathology) 2020 risk classification system with the previous 2016 risk classification in predicting survival and patterns of recurrence in the Danish endometrial cancer population.

Methods: This Danish national cohort study included 4516 patients with endometrial cancer treated between 2005 and 2012. Five-year Kaplan-Meier adjusted and unadjusted survival estimates and actuarial recurrence rates were calculated for the previous and the new classification systems. Read More

View Article and Full-Text PDF

Adjuvant Therapy for High-risk Endometrial Carcinoma.

Authors:
J Perera P Hoskin

Clin Oncol (R Coll Radiol) 2021 Jun 7. Epub 2021 Jun 7.

Mount Vernon Cancer Centre, Northwood, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address:

About one-fifth of endometrial cancers are 'high risk', which carries a poorer prognosis. Management strategies to optimise their survival have been under investigation for many years. Despite recent advances, their overall survival remains relatively poor. Read More

View Article and Full-Text PDF

Post-operative volumes following endoscopic surgery for non-functioning pituitary macroadenomas are predictive of further intervention, but not endocrine outcomes.

BMC Endocr Disord 2021 Jun 10;21(1):116. Epub 2021 Jun 10.

Leeds Centre for Diabetes & Endocrinology, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Background: Transsphenoidal surgery (TSS) remains the treatment of choice for non-functioning pituitary macroadenomas (NFPMA). The value of measuring tumour volumes before and after surgery, and its influence on endocrine outcomes and further treatment of the residual or recurrent tumour are unknown.

Methods: Data from patients who underwent endoscopic TSS for a NFPMA (2009-2018) in a UK tertiary centre were analysed for pre- and post-operative endocrine and surgical outcomes. Read More

View Article and Full-Text PDF

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.

Lancet 2021 Jun 4. Epub 2021 Jun 4.

Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.

Background: Patients with locoregionally advanced nasopharyngeal carcinoma have a high risk of disease relapse, despite a high proportion of patients attaining complete clinical remission after receiving standard-of-care treatment (ie, definitive concurrent chemoradiotherapy with or without induction chemotherapy). Additional adjuvant therapies are needed to further reduce the risk of recurrence and death. However, the benefit of adjuvant chemotherapy for nasopharyngeal carcinoma remains controversial, highlighting the need for more effective adjuvant treatment options. Read More

View Article and Full-Text PDF

Nivolumab as adjuvant treatment for a spinal melanocytoma: A case report.

Medicine (Baltimore) 2021 May;100(19):e25862

Département d'Oncologie Médicale, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez.

Rationale: Meningeal melanocytoma is a rare benign melanocytic tumor of the central nervous system. We report for the first time a case of meningeal melanocytoma treated with immunotherapy.

Patient Concerns: A 70-year-old man with no medical history was admitted to the Emergency Room. Read More

View Article and Full-Text PDF

The impact of adjuvant treatment with external beam radiotherapy and vaginal brachytherapy on health-related quality of life in patients with early-stage endometrioid endometrial carcinoma - initial results of a prospective study.

Ginekol Pol 2021 Jun 9. Epub 2021 Jun 9.

Department of Radiotherapy, Chair of Oncology, Medical University of Lodz, Poland.

Objectives: Our study evaluates the impact of adjuvant treatment with external beam radiotherapy (EBRT) combined with vaginal high-dose-rate brachytherapy (HDR BT) on health-related quality of life (HRQL) in patients with early-stage endometrioid endometrial carcinoma.

Material And Methods: We assessed HRQL of patients based on the EORTC QLQ-C30 questionnaire, with endometrial cancer specific HRQL module - EORTC QLQ-EN24. From March 2019 to April 2020 we enrolled 20 patients with early-stage endometrioid endometrial carcinoma, qualified for adjuvant treatment after hysterectomy. Read More

View Article and Full-Text PDF

Review of Perineural Invasion in Keratinocyte Carcinomas.

Am J Clin Dermatol 2021 Jun 8. Epub 2021 Jun 8.

Brooklyn Campus of the VA NY Harbor Healthcare System, 800 Poly Place, Brooklyn, NY, 11209, USA.

Perineural invasion is an infiltrative process of peripheral nerves by the primary neoplasm within the immediate vicinity. Aggressive forms of keratinocyte carcinomas, such as basal cell and squamous cell carcinomas, may feature perineural invasion, which is often associated with tumor recurrence and poorer prognosis. Diagnosis requires a high clinical suspicion. Read More

View Article and Full-Text PDF

Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes.

J Neurooncol 2021 Jun 8. Epub 2021 Jun 8.

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA.

Purpose: We report disease control, survival outcomes, and treatment-related toxicity among adult medulloblastoma patients who received proton craniospinal irradiation (CSI) as part of multimodality therapy.

Methods: We reviewed 20 adults with medulloblastoma (≥ 22 years old) who received postoperative proton CSI ± chemotherapy between 2008 and 2020. Patient, disease, and treatment details and prospectively obtained patient-reported acute CSI toxicities were collected. Read More

View Article and Full-Text PDF

Adjuvant treatment in lung cancer.

J Clin Transl Res 2021 Apr 16;7(2):175-184. Epub 2021 Apr 16.

Department of Radiation Oncology, Hospital Universitario Santiago de Compostela. Tr Choupana S/N, 15706 Santiago de Compostela, Spain.

Background: Adjuvant treatment for both small-cell and non-small-cell lung cancer is a controversial topic. There are no published results from prospective studies that either confirm or reject the benefit of adjuvant radiotherapy, although the presentation of recent studies at a number of conferences questions whether there should be a change in the paradigm of adjuvant RT for lung cancer.

Aim: The main goal of this study is to review the most relevant publications on the topic, updating the state of the matter regarding adjuvant radiotherapy following lung surgery, and analyzing the role of chemotherapy in the process. Read More

View Article and Full-Text PDF

Recent advances in early stage lung cancer.

J Clin Transl Res 2021 Apr 6;7(2):163-174. Epub 2021 Apr 6.

Department of Radiation Oncology, Ruber International, Madrid, Spain.

Treatment of early-stage non-small cell lung cancer has undergone considerable change in recent years. Areas of great interest to researchers include less invasive surgical methods with lower associated morbidity, indications for adjuvant chemotherapy and radiotherapy, the emergence of stereotactic body radiotherapy (SBRT) for peripheral and central or ultracentral tumors, and the probable role of adjuvant immunotherapy following surgery and SBRT, all of which may influence the management of these patients.

Relevance For Patients: At present, the treatment of early stage non-small cell lung cancer is undergoing changes associated with the evolution of existing treatments and the advent of new treatments. Read More

View Article and Full-Text PDF

The current role of surgery and SBRT in early stage of small cell lung cancer.

J Clin Transl Res 2021 Feb 17;7(1):34-48. Epub 2021 Feb 17.

Department of Thoracic Surgery, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.

Background: Early stage small cell lung cancer (T1-2N0M0SCLC) represents 7% of all SCLC. The standard treatment in patients with intrathoracic SCLC disease is the use of concurrent chemoradiotherapy (CRT). Nowadays, the recommended management of this highly selected group is surgical resection due to favorable survival outcomes. Read More

View Article and Full-Text PDF
February 2021

Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial.

Ther Adv Endocrinol Metab 2021 5;12:20420188211012118. Epub 2021 May 5.

Department of Medicine (Austin Health), The University of Melbourne, VIC, Australia.

Background: Animal studies suggest that undercarboxylated osteocalcin may improve insulin sensitivity its effect on testicular testosterone production. Human studies have been conflicting. Men undergoing androgen deprivation therapy (ADT) for prostate cancer experience profound hypogonadism resulting in increased insulin resistance. Read More

View Article and Full-Text PDF

Can early salvage radiotherapy replace adjuvant radiotherapy as the new standard of care for high-risk postradical prostatectomy patients?

Authors:
Abhishek Pandey

Indian J Urol 2021 Apr-Jun;37(2):195-196. Epub 2021 Apr 1.

Department of Urology, AIIMS, Bhubaneshwar, Odisha, India.

View Article and Full-Text PDF

Epigenetic mechanisms underlying prostate cancer radioresistance.

Clin Epigenetics 2021 Jun 8;13(1):125. Epub 2021 Jun 8.

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Vico L. De Crecchio 7, 80138, Naplei, Italy.

Radiotherapy (RT) is one of the mainstay treatments for prostate cancer (PCa), a highly prevalent neoplasm among males worldwide. About 30% of newly diagnosed PCa patients receive RT with a curative intent. However, biochemical relapse occurs in 20-40% of advanced PCa treated with RT either alone or in combination with adjuvant-hormonal therapy. Read More

View Article and Full-Text PDF

Oncologic outcomes of transoral robotic surgery for HPV-negative oropharyngeal carcinomas.

Head Neck 2021 Jun 8. Epub 2021 Jun 8.

Department of Otorhinolaryngology - Head & Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Background: Patients with human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) continue to experience disappointing outcomes following chemoradiotherapy (CRT) and appreciable morbidity following historical surgical approaches. We aimed to investigate the oncologic outcomes and perioperative morbidity of a transoral robotic surgery (TORS) approach to surgically resectable HPV-negative OPSCC.

Methods: Retrospective analysis HPV-negative OPSCC patients who underwent TORS, neck dissection and pathology-guided adjuvant therapy (2005-2017). Read More

View Article and Full-Text PDF

Salvage surgery after definitive chemoradiotherapy through VATS for an initial unresectable locally advanced lung cancer: an alternative consolidative modality to radiotherapy?

Surg Case Rep 2021 Jun 8;7(1):138. Epub 2021 Jun 8.

Division of Thoracic Oncology, Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Background: Definitive chemoradiotherapy (dCRT) is the first choice treatment for patients with locally advanced non-small cell lung cancer (NSCLC), but up to 35% of dCRT-treated tumors may have persistent or recurrent disease. Since the last decades, multimodality therapy showing potential for cure has become the mainstream for treatment of locally advanced NSCLCs, even some that were initially inoperable. Although salvage lung resection after dCRT has been reported with acceptable survivals, experiences in this respect are still limited. Read More

View Article and Full-Text PDF